Lifeboat Foundation

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in the field of protein design, as new enzymes could have many uses across medicine and industrial manufacturing.

“Living organisms are remarkable chemists. Rather than relying on toxic compounds or extreme heat, they use enzymes to break down or build up whatever they need under gentle conditions. New enzymes could put renewable chemicals and biofuels within reach,” said senior author David Baker, professor of biochemistry at the University of Washington School of Medicine and recipient of the 2021 Breakthrough Prize in Life Sciences.

As reported Feb, 22 in the journal Nature, a team based at the Institute for Protein Design at UW Medicine devised machine-learning algorithms that can create light-emitting enzymes called luciferases. Laboratory testing confirmed that the new enzymes can recognize specific chemicals and emit light very efficiently. This project was led by two postdoctoral scholars in the Baker Lab, Andy Hsien-Wei Yeh and Christoffer Norn.

The bones of the face and skull can be affected due to a wide range of conditions, including cleft palate defects, traumatic injuries, cancer, and bone loss from dentures. Although bone replacements are routinely used to regenerate the missing tissue, they are vulnerable to bacterial infection. In a new study, researchers investigated whether manuka honey, made from tea trees, can be used to resist bacterial infection and promote bone growth.

Bone implants account for 45% of all hospital-contracted infections, impeding healing. Typically, these implants are made from biomaterials that contain extracellular matrix components—molecules that provide structural support to cells. However, researchers commonly use metal implants or synthetic polymers to study bone defects and infections. Therefore, there is a gap in the understanding of how biomaterials behave in response to infection.

“Imagine a metal versus something soft and porous that is made up of extracellular matrix components. They have very different characteristics,” said Marley Dewey, a former graduate student in the Harley lab and the first author of the paper. “Using our scaffolds, this is the first paper to look at how these materials become infected.”

Apple Inc. has a moonshot-style project underway that dates back to the Steve Jobs era: noninvasive and continuous blood glucose monitoring.

Scientists continue to make intriguing breakthroughs that could help reshape our lives. This time, a group of scientists managed to create a shape-shifting liquid metal that can transition between the solid and liquid state. The new liquid is reminiscent of the liquid shapeshifting seen in 1991’s Terminator 2, and the scientists even tested it by having it escape a cage.

The scientists published a paper on the new shape-shifting liquid in the journal Matter. In it, they discuss how they created the metal and the rigorous tests they put it through. For the most part, the scientists created the liquid in the form of small robots, which they were then able to shift between solid and liquid states to jump, climb, and – as noted above – even ooze out of a cage to freedom.

Continue reading “Researchers invented a liquid metal robot that can shapeshift like a Terminator” »

Researchers are announcing that a 53-year-old man in Germany has been cured of HIV.

Referred to as “the Dusseldorf patient” to protect his privacy, researchers said he is the fifth confirmed case of an HIV cure. Although the details of his successful treatment were first announced at a conference in 2019, researchers could not confirm he had been officially cured at that time.

Today, researchers announced the Dusseldorf patient still has no detectable virus in his body, even after stopping his HIV medication four years ago.

In a recent study published in Cell, researchers presented eight hallmarks of neurodegenerative diseases (NDDs), their in vivo biomarkers, and interactions to help categorize NDDs and specify patients within a specific NDD.

Despite being linked to rare genetic forms, all eight NDD hallmarks (cellular/molecular processes) also contribute to sporadic NDDs. In addition, they contribute to neuronal loss in preclinical (animal) models and NDD patients, manifesting as an altered molecular (hallmark) biomarker.

An NDD patient could have defects in multiple NDD hallmarks. However, the primary NDD hallmark depends on the NDD insult and the neuronal susceptibility and resilience, i.e., one’s ability to handle insults in the affected brain region.

Scientists have identified the exact point at which healthy brain proteins are shocked into the tangled mess that is commonly associated with Alzheimer’s disease.

Researchers at the University of California Santa Barbara (UCSB) are h opeful that the new laboratory technique behind the discovery can be used to directly study the ‘never-before-seen’ early stages of many neurodegenerative diseases.

Tau proteins are abundant in the human brain. At first, these proteins look like tiny pieces of string inside neurons. As they fold and bind together with structural elements called microtubules, however, they create a sort of skeleton for brain cells that helps them function properly.

19 minutes in, “At this point I think things are going pretty damned well,” when talking about if the middle-aged will benefit.

Life-Extension pioneer Dr. Aubrey De Grey discusses the LEV & SENS foundations, the latest trends in anti-aging research, new animal trials anticipated to double or triple life expectancy, and increased social acceptance for the disease model of aging.

Continue reading “Aubrey de Grey — Longevity & Life-Extension” »

Glioblastomas are the most common malignant tumors of the adult brain. They resist conventional treatment, including surgery, followed by radiation therapy and chemotherapy. Despite this armamentarium, glioblastomas inexorably recur.

In a new study published in Nature Communications, Isabelle Le Roux (CNRS) and her colleagues from the “Genetics and development of brain tumors” team at Paris Brain Institute have shown that the elimination of senescent cells, i.e., cells that have stopped dividing, can modify the tumor ecosystem and slow its progression. These results open up new avenues for treatment.

Glioblastoma, the most common adult brain cancer, affects 2 to 5 in 100,000 individuals. While the incidence of the disease is highest in those between 55 and 85 years old, it is increasing in all age groups. This effect can’t be attributed to improved diagnostic techniques alone, suggesting the influence of environmental factors hitherto unidentified.